Tourette syndrome (TS) is an inheritable, childhood-onset neurologic disorder marked by persistent multiple motor tics and at least one vocal tic (1).* Tics are involuntary, repetitive, stereotypic movements or vocalizations that are usually sudden and rapid and often can be suppressed for short periods (1). The prevalence of TS is uncertain; the broad range of worldwide estimates, from 1-30 per 1,000 population (2,3), likely is the result of differences in study methodology. This report presents the first estimate of national prevalence of diagnosed TS among a national sample of U.S. children and adolescents aged 6-17 years. Based on data from the 2007 National Survey of Children's Health (NSCH) (4), the estimated prevalence of a lifetime diagnosis of TS by parent report was 3.0 per 1,000. A diagnosis of TS was almost three times as likely for boys as girls, twice as likely for persons aged 12-17 years than for those aged 6-11 years, and twice as likely for non-Hispanic white persons than for Hispanic and non-Hispanic black persons. Among persons ever diagnosed with TS, 79% also had been diagnosed with at least one co-occurring mental health or neurodevelopmental condition. CDC sponsors efforts by the Tourette Syndrome Association to educate health-care providers and school personnel about TS to ensure earlier identification and promote appropriate medical, educational, and comprehensive behavioral interventions for children with TS and co-occurring mental health or neurodevelopmental conditions.
Tourette syndrome (TS) is an inheritable, childhood-onset neurologic disorder marked by persistent multiple motor tics and at least one vocal tic (1) .* Tics are involuntary, repetitive, stereotypic movements or vocalizations that are usually sudden and rapid and often can be suppressed for short periods (1) . The prevalence of TS is uncertain; the broad range of worldwide estimates, from 1-30 per 1,000 population (2, 3) , likely is the result of differences in study methodology. This report presents the first estimate of national prevalence of diagnosed TS among a national sample of U.S. children and adolescents aged 6-17 years. Based on data from the 2007 National Survey of Children's Health (NSCH) (4), the estimated prevalence of a lifetime diagnosis of TS by parent report was 3.0 per 1,000. A diagnosis of TS was almost three times as likely for boys as girls, twice as likely for persons aged 12-17 years than for those aged 6-11 years, and twice as likely for non-Hispanic white persons than for Hispanic and non-Hispanic black persons. Among persons ever diagnosed with TS, 79% also had been diagnosed with at least one co-occurring mental health or neurodevelopmental condition. CDC sponsors efforts by the Tourette Syndrome Association to educate health-care providers and school personnel about TS to ensure earlier identification and promote appropriate medical, educational, and comprehensive behavioral interventions for children with TS and co-occurring mental health or neurodevelopmental conditions.
The 2007 NSCH was the first national, population-based survey of persons aged <18 years that included questions on TS (4) . NSCH is a random-digit-dialed telephone (landline only) survey used to estimate the prevalence of a variety of child health and well-being indicators for every state and to examine these indicators together with information on family characteristics and neighborhood environment. † Telephone interviews (N = 91,642) were completed with parents (or guardians) from April 2007 through July 2008. One child was randomly selected from each household to be the focus of the interview. Complete data on TS were available for 64,034 persons aged 6-17 years. The overall response rate was 46.7%; the cooperation rate was 66.0%. § Data were weighted to account for unequal probability of selection of each household and child, for nonresponse, and for households without landline telephones. Weights were adjusted further so that estimates reflected the demographic distribution of * Diagnostic criteria for Tourette syndrome include 1) the presence of multiple motor and one or more vocal tics at some time during the illness, although not necessarily concurrently; 2) occurrence of tics many times a day, nearly every day, or intermittently throughout a period of more than 1 year, with no tic-free period of more than 3 consecutive months; 3) onset before age 18 years; and 4) symptoms not caused by direct physiologic effects of a substance or a general medical condition (1) . Parents were asked, "Has a doctor or other health-care provider ever told you that [your child] had Tourette syndrome?" Affirmative responses were followed by asking whether the child currently has TS, and if so, whether the parent would describe the child's TS as mild, moderate, or severe (severity was only assessed for current TS). The same series of questions (e.g., current or ever doctor diagnosis) were asked about other co-occurring conditions, including attention-deficit/ hyperactivity disorder (ADHD), depression, anxiety problems, behavioral or conduct problems such as oppositional defiant disorder or conduct disorder, and developmental delays affecting a child's ability to learn. Prevalence of parent-reported TS diagnosis (ever and current) among U.S. children, presence of co-occurring conditions, and severity of symptoms among children with current TS were calculated using statistical analysis software to account for the complex sampling design of NSCH.
All estimates in this report reflect persons aged 6-17 years. Estimates for children aged <6 years had high relative standard errors (>0.3) and are not reported. The estimated prevalence for ever receiving a TS diagnosis, by parent report, was 3.0 per 1,000, representing approximately 148,000 children (95% confidence interval [CI] = 111,000-197,000) ( Table) in the United States. A diagnosis of TS was approximately three times as likely for boys compared with girls, and approximately twice as common in persons aged 12-17 years compared with those aged 6-11 years. Non-Hispanic white children were twice as likely as non-Hispanic black children and Hispanic children to have a parent-reported TS diagnosis. No differences were noted by parental education or household income. Among children ever diagnosed with TS, 79% also had been diagnosed with at least one co-occurring mental health or neurodevelopmental condition ( Figure) : 64% had been diagnosed with ADHD, 43% with behavioral or conduct problems, 40% with anxiety problems, 36% with depression, and 28% with a developmental delay affecting the child's ability to learn.
Among children with a TS diagnosis, 62% (weighted N = approximately 92,000, CI = 65,000-131,000) were described as currently having TS. Most current cases were described as mild, and 27.1% (CI = 15.0-43.8) were rated as moderate or severe. Persons aged 6-13 years were more likely than those aged 14-17 years to currently have TS (82.6% versus 42.1%, p<0.01). Differences between the 6-11 years and 12-17 years age groups were not statistically significant.
* Selected diagnoses included mental health and neurodevelopmental
conditions asked about on the survey, including attention-deficit/hyperactivity disorder (ADHD), behavioral or conduct problems, anxiety problems, depression, and developmental delays. † Among children ever diagnosed with TS, 79% also had been diagnosed with at least one other selected diagnosis. Among children who currently have TS, 73% currently have at least one additional selected diagnosis. § 95% confidence interval. ¶ Attention-deficit disorder or attention-deficit/hyperactivity disorder, by parent report. ** Such as oppositional defiant disorder or conduct disorder, by parent report. 
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Many studies have reported male-to-female TS prevalence ratios of at least 4:1 (3, 9, 10) . This is consistent with the higher prevalence of TS diagnosis among boys observed in the NSCH data. The reason boys are more likely than girls to express symptoms of TS is unclear and is likely the result of a combination of genetic, hormonal, and environmental factors (1, 8) .
The higher lifetime prevalence among older children is consistent with the known age distribution. Although average age of tic onset is 5-7 years, the course is often insidious (8) . Severity often peaks between ages 10 and 12 years (8) . Thus, the onset of TS symptoms might not be recognized immediately by parents or diagnosed by a clinician. After tic severity peaks, it might decline sufficiently that parents will no longer report that their child has TS. Among all children ever receiving a TS diagnosis, current TS was less likely to be reported for persons aged 14-17 years. However, impairment can endure into adulthood (8) , and early identification and intervention might improve social, educational, and employment outcomes for persons with TS.
Consistent with community-based studies (2,9), approximately three fourths of children in this study with a current TS diagnosis had mild TS, according to their parents. Even when TS is mild, however, commonly associated co-occurring conditions such as ADHD and obsessive compulsive disorder might contribute to overall impairment (2,10).
The survey-based prevalence estimate described in this report is based on parent report of a TS diagnosis. The detection and diagnosis of TS is less likely for children with limited access to specialty health-care services (2) . Thus, the observed surveybased prevalence of 3.0 per 1,000 likely is an underestimate of TS prevalence in children. Results from community-based studies that independently evaluate children for TS and do not rely on parent-reported diagnosis invariably identify cases that were previously not diagnosed (3, 6, 9) . In addition, many children identified as having TS in community-based studies were not receiving mental health services (2, 6, 9) . This suggests that primary-care practices and schools might be important settings to improve recognition and referral.
The survey-based prevalence estimates revealed that nonHispanic black children and Hispanic children had a lower probability of TS diagnosis compared with non-Hispanic white children. Community-based studies of TS have lacked adequate sample size to determine prevalence for racial or ethnic groups. Differences in the prevalence of TS among racial and ethnic groups might result from biologic risk or disparities in access to specialty health care. The gap between prevalence reported in community-based studies and surveybased prevalence described in this report among non-Hispanic blacks and Hispanics is greater than the gap between reports from community-based studies and the survey-based prevalence among non-Hispanic whites. These gaps support the view that differences in reported prevalence are at least partially attributable to differences in access to care. The lack of association between income and parent education with TS diagnosis suggests that other factors might affect the racial and ethnic differences. Research in communities with adequate representation of minority and underserved populations is needed to clarify the reasons for the differences in prevalence.
The findings in this report are subject to at least four limitations. First, symptoms consistent with TS must be recognized to establish a diagnosis. Some cases might remain undetected because of lack of awareness or access to medical care. Second, families who did not speak English, Spanish, or one of four Asian languages (Cantonese, Korean, Mandarin, or Vietnamese) were excluded from the survey (4). Third, the presence of co-occurring conditions and reported severity might be subject to recall error. Finally, the results are subject to biases associated with telephone surveys, including the exclusion of households without landlines and low response rates relative to population-based, face-to-face surveys.
Impairment in learning, school performance, and social competence can result from tics or co-occurring conditions (2) . Clinical assessment and treatment of children with TS warrants attention to tics and co-occurring conditions to reduce overall impairment. The degree of impairment and spectrum of co-occurring conditions varies and therefore the treatment should be tailored to address the individual's type and severity of symptoms. Assessment by a specialist (e.g. pediatric neurologist or child psychiatrist), might provide the best available treatment options (e.g., behavioral or pharmacologic interventions). If academic or behavioral performance is of concern, referrals for educational interventions designed to reduce the effect of tics and co-occurring disruptive behavioral problems on learning should be considered.
Defining lifetime prevalence is an important step in defining the public health impact of TS. Although symptoms of TS might disappear in some cases by early adulthood, symptoms of co-occurring conditions can persist. CDC is conducting surveillance, research, and outreach activities to document the impact of TS and improve its recognition. CDC sponsors the Tourette Syndrome Association to provide authoritative education for physicians and allied health care workers, including school personnel, about TS treatment and the effects of the disorder. The programs increase access to accurate and scientifically valid information on the recognition, diagnosis, and treatment of TS, with a view toward improved health and developmental outcomes. 
Update

Enhanced Surveillance
The outbreak of acute respiratory illness in La Gloria, Veracruz (population 2,155), was characterized by a large number of cases (616 or 28.5% of the population) reported during March 5-April 10. This outbreak was likely of mixed cause; later testing of respiratory specimens collected during this period identified two patients as positive for seasonal influenza A (H3N2), one for seasonal influenza B, and one patient for novel influenza A (H1N1) virus with an adenovirus coinfection. Most of the respiratory illnesses from this outbreak remain undiagnosed; no severe cases or deaths were observed.
During March and April, 47 cases of rapidly progressive severe pneumonia were identified from clusters in Mexico City, San Luis Potosi, and other cities. Twelve deaths were reported; in four of the deaths, specimens were positive for novel influenza A (H1N1) infection. In response to the La Gloria outbreak and the pneumonia clusters, the National Committees for Epidemiological Surveillance and Emerging Infectious Disease released an epidemiologic alert on April 17 to enhance national surveillance for acute respiratory illness and severe pneumonia. This enhanced surveillance was implemented through active case finding in hospitals throughout the country, including daily zero-reporting (requiring facilities and jurisdictions to report even if no suspected cases had been identified) and monitoring of news media and other sources. (Table) . Forty-nine percent of patients with confirmed infection were female.
As of May 29, Distrito Federal (Mexico City) had the highest number of laboratory-confirmed novel influenza A (H1N1) cases (1,804) and deaths (38); Mexico State reported 21 deaths (Figure 1 ). The peak number of confirmed cases (375) had onset of April 27 ( Figure 2 ). As of May 29, all states in Mexico had reported laboratory-confirmed cases of novel influenza A (H1N1) virus.
Control Measures
On April 24, the federal government of Mexico activated the National Pandemic Preparedness and Response Plan and announced closure of schools in metropolitan Mexico City. Concurrently, the Ministry of Health launched a mass media campaign to promote respiratory hygiene and to alert the public about transmission of influenza. Additional social distancing measures included closure of restaurants and entertainment venues and cancellation of large public gatherings nationwide. To date, Mexico continues enhanced national surveillance and early antiviral treatment to decrease transmission of novel influenza A (H1N1) virus. Respiratory hygiene and hand washing are promoted through television and print media. On May 11, as schools reopened, parents were reminded to keep their children home if they had symptoms of influenza. In addition, a team of teachers and parents screened children at school entrances to determine whether they had fever or respiratory symptoms. The Ministries of Education and Health recommended closure of classrooms where two or more children had respiratory symptoms and closure of schools with ill children in two or more classrooms. On the first day of using this strategy, 91,357 children were determined symptomatic. This screening at schools was suspended on May 23. Screening for respiratory illness is ongoing at airports, where passengers complete a brief questionnaire about respiratory symptoms. Symptomatic travelers are asked to delay their journeys and referred for medical evaluation. At Mexico City's International Airport, thermal scanners of body temperatures also are in use.* Editorial Note: Trends in case counts in Mexico suggest that novel influenza A (H1N1) activity is now decreasing, although localized transmission continues to occur. The epidemic curve of laboratory-confirmed cases remains incomplete because of a backlog of untested specimens. However, data regarding suspected cases (3) also indicate a peak in late April, and delays from case identification to reporting have decreased to a median of <2 days (Mexico Office of the Secretary of Health, unpublished data, 2009). Taken together, these data suggest that the outbreak likely has moved beyond its peak nationally, although a pattern of heterogeneous transmission and focal outbreak activity remains. Several features of the outbreak in Mexico are consistent with outbreaks of the same novel influenza virus strain circulating in the United States and other countries. These features include person-to-person transmission during a period that is typically the low season for circulation of influenza viruses (4) and an age distribution of laboratory-confirmed cases that includes severe disease and deaths among children and adults in Mexico aged <60 years (4). Some deaths have occurred among previously healthy persons (4), and several patients have experienced an aggressive clinical course with severe pneumonia requiring ventilator support and progression to acute respiratory distress syndrome (2, 5, 6) .
A recently reported serologic study suggested that children and younger adults have no or low levels of serum antibody, respectively, that are cross-reactive for the novel influenza A (H1N1) virus. Approximately one third of U.S. adults aged >60 years who were tested had cross-reactive neutralizing antibodies; however, the extent to which such antibody might be protective remains unknown (7) . The serologic data, along with the age distribution of illness and clinical severity from the outbreak in Mexico, suggest age <60 years as a risk for infection and serious illness from novel A (H1N1) infection.
The current pattern of novel influenza A (H1N1) transmission in the northern hemisphere includes many localized outbreaks, including several among school children (8) . This pattern is consistent with influenza outbreaks occasionally reported outside of the usual influenza season (9) . However an unprecedented number of such off-season outbreaks are occurring currently. These outbreaks also involve extension into the community, as demonstrated by confirmed illness among travelers with no known epidemiologic link to focal outbreaks. Similar patterns of off-season outbreaks have been observed previously with the emergence and sustained transmission of other novel influenza A virus strains among humans (10) .
The recent introduction of novel influenza A (H1N1) into several countries in the southern hemisphere at the beginning of its influenza season and the presumed susceptibility among much of the population to this new virus suggest that this strain might become a dominant circulating virus in the southern hemisphere during the coming months. The government of Mexico continues to coordinate a national response, engage partners, increase surge capacity, and implement mitigation measures to slow the spread of novel influenza A (H1N1). Investigations are ongoing to monitor virus circulation and evaluate mitigation strategies that might help guide prevention and control strategies in Mexico and worldwide. Data were categorized by sex, age group, and mode of HIV transmission. The following hierarchy was used for HIV transmission categories: 1) male-to-male sexual contact, 2) injection-drug use, 3) male-to-male sexual contact and injection-drug use, and 4) high-risk heterosexual contact (i.e., with a sex partner known to have or to be at high risk for HIV infection). The number of reported diagnoses was adjusted for reporting delay using a previously reported procedure (3). In addition, for diagnosed cases missing transmission category (32%), a multiple imputation procedure was used (4). Percentages were calculated for sex, age group, and transmission categories. HIV diagnosis rates per 100,000 population were calculated for sex and age group using postcensus estimates for 2006 (5) .
HIV incidence for Puerto Rico was calculated using the stratified extrapolation approach (2, 6) . Remnant diagnostic serum specimens from persons aged >13 years and diagnosed with HIV infection in 2006 in Puerto Rico were tested with the BED HIV-1 capture enzyme immunoassay (BED) to classify infections as recent or long-standing. In addition to the BED result, the estimation method requires HIV testing history, demographic data, and behavioral information for persons with HIV infection diagnosed in 2006. HIV incidence was calculated from cases based on the 1,021 diagnoses of HIV infection, adjusted to 1,460 for reporting delays in 2006. Percentages were calculated for sex, age group, and transmission categories. HIV incidence rates per 100,000 population were calculated for sex and age group using official postcensus estimates for 2006 (5) .
In 2006, after adjustment for reporting delays, 1,460 persons aged >13 years were diagnosed with HIV infection in Puerto Rico (Table 1 ). Of these, 1,036 (71%) were males and 424 (29%) were females. By age group, the greatest number of diagnoses of HIV infection occurred among those aged 30-39 years, followed by those aged 40-49 years. Among males, the most common mode of HIV transmission was injection-drug use (40%), followed by male-to-male sexual contact (30%). Among females, the most common mode of HIV transmission was high-risk heterosexual contact (73%), followed by injection-drug use (27%). The rate of diagnosis of HIV infection in Puerto Rico in 2006 was 45.5 per 100,000 population.
An estimated 1,440 persons (45.0 per 100,000 population) were newly infected with HIV in 2006. The HIV incidence rate among males (62.0) was twice that among females (29.8). The highest rate of incident HIV infections, among persons aged 30-39 years (103.6), was 1.7 times that of the age group with the next highest rate (40-49 years [59.3]). The mode of transmission with the greatest number of new HIV infections was injection-drug use (39%), followed by high-risk heterosexual contact (37%) and male-to-male sexual contact (24%) ( Editorial Note: These estimates of HIV incidence in Puerto Rico in 2006 reveal important differences between HIV epidemiology in Puerto Rico and the 50 U.S. states and DC. The overall HIV incidence rate in Puerto Rico in 2006 (45.0 per 100,000 population) was twice the estimated U.S. rate (22.8) and 1.5 times the estimated rate for Hispanics in the United States (29.4). The incidence rate among males in Puerto Rico (62.0) was 1.8 times the rate among U.S. males (34.3) and 1.4 times the rate among U.S. Hispanic males (43.1). The incidence rate among females in Puerto Rico (29.8) was 2.5 times the rate among U.S. females (11.9) and 2.0 times the rate in U.S. Hispanic females (14.4) (6,7). However, comparisons between the rates for Puerto Rico and the rates for Hispanics in the United States should consider differences in the two populations. Hispanics in the United States include persons who are U.S. born and those of diverse national origin whose behavioral characteristics might differ from Hispanics in Puerto Rico (8) . In addition, the number of diagnoses of HIV infection generally is higher in metropolitan areas, and population density in Puerto Rico (1,112 persons per square mile) is 14 times that of the United States (79.6 persons) (1, 6, 7, 9) .
Injection-drug use continues to be the most common mode of HIV transmission in Puerto Rico, whereas most new HIV infections in the 50 U.S. states and DC are attributed to maleto-male sexual contact (1, (6) (7) (8) . Previous reports have indicated greater prevalence of injection-drug use and high-risk health behaviors related to injection-drug use (e.g., frequency of injecting and sharing syringes and other drug paraphernalia) in Puerto Rico than in the United States (8) . In 2006, most new HIV infections in the United States, including among Hispanics, occurred in persons aged 13-29 years (7) . In contrast, most new HIV infections in Puerto Rico occurred among persons aged 30-39 years. This age group had the highest rates of new HIV infection in both Puerto Rico and the United States; however, the incidence rate in Puerto Rico (103.6 per 100,000 population) was 2.4 times the rate in the United States (42.6) (6). One possible explanation for the higher rates in this age group in Puerto Rico might be related to injection-drug use. Persons commonly begin using noninjection drugs and progress to injection-drug use. However, further investigation is needed to test that hypothesis and fully understand the reasons for difference in the rates.
The findings in this report are subject to at least two limitations. The classification of cases reported without a risk factor for transmission was based on a model incorporating random variations to impute missing values (4). Although multiple imputation procedures are designed to maintain associations within the data, the degree of uncertainty introduced by this imputation procedure is unknown. Second, the stratified extrapolation approach to HIV incidence estimation is based on several key assumptions, including that information on previous tests and BED results were missing at random, that testing behavior has not changed substantially over several years, that testing and infection are independent, and that information on previous testing is accurate (2) . Concerns have been raised about the accuracy of the BED test, which appeared to result in overestimation of recent HIV infections in Africa and Thailand (10) . The implications of these assumptions on incidence estimation have been discussed extensively (2, 6) The HIV epidemic in Puerto Rico is notably different from the epidemic in the United States overall and among Hispanics in the United States (1, (6) (7) (8) . CDC supports prevention efforts that target populations at greatest risk in Puerto Rico, including injection-drug users, women who have high-risk heterosexual contact, men who engage in male-to-male sexual contact, and youths. To address transmission of HIV infection among injection-drug users, the Puerto Rico Department of Health provides syringe exchange programs and rapid HIV testing, has implemented policies to allow pharmacies to sell syringes without medical prescription, and provides drug rehabilitation services throughout the country. The findings in this report help describe the HIV epidemic in Puerto Rico and can help guide future allocation of resources and planning, implementation, and evaluation of HIV prevention programs and services.
Impact of New WHO Growth Standards on the Prevalence of Acute Malnutrition and Operations of Feeding Programs -Darfur, Sudan, 2005-2007
Acute malnutrition among children aged 6-59 months is a key indicator routinely used for describing the presence and magnitude of humanitarian emergencies. In the past, the prevalence of acute malnutrition and admissions to feeding programs has been determined using the growth reference developed by the World Health Organization (WHO), CDC, and the National Center for Health Statistics (NCHS 
For the immediate future, the prevalence of acute malnutrition in children should be reported using both the old WHO/ CDC/NCHS reference and the new WHO standards. More research is needed to better ascertain the validity of the admission criteria based on the new WHO standards in predicting malnutrition-related morbidity and mortality.
Historically, measures of acute malnutrition have been based on the WHO/CDC/NCHS growth reference (1). This reference is a normalized version of the 1977 NCHS reference (2) . The NCHS reference is based on data from predominantly formula-fed children collected in the United States during the 1960s and 1970s. However, at least one report has indicated a need for more internationally representative, up-to-date growth standards based on predominantly breastfed children (3). Therefore, in 2006, WHO developed new growth standards using data collected during 1997-2003 from predominantly breastfed children living in favorable conditions from sites in six regions of the world (4, 5) . The WHO growth standards are considered preferable because they represent how healthy children should grow, whereas the WHO/CDC/NCHS reference only represents how children grew in a specific place and time (4) .
To describe acute malnutrition at the population level, two prevalence indicators are normally reported: global acute malnutrition (GAM) and severe acute malnutrition (SAM) (6) . GAM and SAM are the principal indicators reported in nutrition surveys and are used to compare population prevalence of acute malnutrition across time and geographic areas. Prevalences of GAM and SAM are based on the proportion of children aged 6-59 months whose weight and height categorize them below a certain Z-score (Table 1) . A Z-score is the number of standard deviations from the weight of an individual child to the reference mean weight, for a given height and sex.
To determine the need for admission to a selective feeding program, children are classified as being moderately malnourished (eligible for supplementary feeding programs) or severely malnourished (eligible for therapeutic feeding programs). In contrast to population prevalence measures (GAM and SAM), this classification has been based previously on the percentage of the median of the WHO/CDC/NCHS growth reference, as opposed to Z-scores (Table 1) . Percentage median is the ratio of the weight of an individual child to the reference mean weight, for a given height and sex. The new WHO guidelines recommend that Z-scores be used not only for measures of population prevalence but also as admission criteria for feeding programs, eliminating use of the percentage median (7), because Z-scores more accurately take into account the distribution of the anthropometric measures within the population. These standards have been endorsed by other United Nations agencies and international health and nutrition bodies (e.g., the United Nations Standing Committee on Nutrition and the International Pediatric Association) and has been adopted in approximately 90 countries (7) .
CDC analyzed data obtained from three annual crosssectional nutritional surveys conducted during [2005] [2006] [2007] in Darfur, Sudan, by the United Nations Children's Fund (UNICEF), the World Food Programme, and CDC. All three surveys obtained anthropometric data from children aged 6-59 months from each of Darfur's three states. Anthropometry scores for each child, including the WHO/CDC/NCHS percentage median, WHO/CDC/NCHS Z-score, and WHO Z-score, were generated.* Records with missing critical data and extreme outliers (e.g., those with Z-scores greater than +4 from the observed mean Z-score) were excluded from analysis.
GAM, SAM, and admission eligibility for moderate and severe acute malnutrition based on the WHO/CDC/NCHS and WHO standards were defined (Table 1) (8) . The prevalences of GAM and SAM were calculated for each annual survey using WHO/CDC/NCHS Z-scores versus WHO Z-scores, and compared by calculating the relative percentage change for years 2005, 2006 , and 2007. To estimate the effects on admissions into feeding programs, the proportions of moderate and severe malnutrition cases were calculated for each annual survey using WHO/CDC/NCHS percentage median versus WHO Z-scores, and compared by calculating the relative percentage change for each year of data. The relative percentage change for combined data from all three years for all measures was calculated. Finally, based on projections of the percentage and numbers of children with SAM, the effects on costs for operating therapeutic feeding programs in Darfur were estimated. A full treatment course for the severely malnourished was assumed to cost $203 (95% confidence interval [CI] = $139-$274) (9) .
When comparing the prevalence of GAM using WHO Z-scores versus WHO/CDC/NCHS Z-scores, an overall relative increase of 14% was observed ( Table 2 ). For SAM, using WHO growth standards resulted in an overall relative increase of 100% compared with WHO/CDC/NCHS-based results. When comparing estimates of eligibility for feeding program enrollment for moderately malnourished children, using WHO Z-scores compared with WHO/CDC/NCHS percentage median indicated an overall relative increase of 56% (Table 3 ). For severely malnourished children, using WHO Z-scores showed an overall relative increase of 260% compared with WHO/CDC/NCHS percentage median.
Analysis of the 2007 data indicated that, by converting from WHO/CDC/NCHS reference to WHO standards, the projected number of severely malnourished children would increase from approximately 6,800 to 30,000. This translates to an increase in operating expenses for therapeutic feeding programs by an estimated $4.7 million (CI = $3.2-$6.3 million). This estimate does not take into account the additional cost for treating moderately malnourished children.
Reported by: O Bilukha, MD, PhD, L Talley, MPH, National Center for Environmental Health; C Howard, MD, EIS Officer, CDC.
Editorial Note: Results of this study demonstrate that transitioning to the new WHO growth standards will have substantial effects on the population prevalence of GAM and SAM, admissions to feeding programs, and costs of program operations. This analysis shows moderate increases in GAM and substantial increases in SAM at levels similar to a previously published report based on displaced populations (10) . Also, based on these estimates, three to four times as many children would be eligible for admission into therapeutic feeding programs.
The findings in this report are subject to at least one limitation. Errors might have occurred during field data collection, which can be challenging in austere settings such as Darfur, where access to the survey population often is limited because of a lack of security and a lack of qualified survey personnel.
CDC recommends that nutrition survey reports on acute malnutrition should, for the immediate future, use both the WHO/CDC/NCHS reference and the WHO standards. Considering the programmatic importance of comparing yearto-year data, if prevalences based only on the WHO growth standards were reported, they could not be compared easily with levels reported from previous years based on WHO/ CDC/NCHS reference. For example, reporting a SAM level of 4.4% using the WHO standard, without explaining that it corresponds to a SAM level of 1.8% based on the WHO/ CDC/NCHS reference, might be somewhat misleading. The guidelines that designate levels of GAM and SAM at which large-scale nutritional interventions are indicated should be updated to reflect expected changes in magnitude of acute malnutrition observed with the new standards. Finally, more Z-score >-3 and <-2 Z-score <-3 or bilateral edema * A Z-score is the number of standard deviations from the weight of an individual child to the reference mean weight, for a given height and sex. † Percentage median is the ratio of the weight of an individual child to the reference mean weight, for a given height and sex. research might be needed to determine what Z-score cutoffs are appropriate for classifying individual children as having moderate or severe acute malnutrition. The focus should be on determining cutoffs that are most sensitive and specific for malnutrition-related morbidity and mortality. If the currently recommended WHO Z-score cutoffs for admission into feeding programs are applied, both the funding and the size of the feeding programs (accounting for the number of trained staff required, infrastructure, and feeding commodities) will have to increase several-fold. If the agencies are not prepared to immediately substantially increase their feeding program funding and operations in parallel with a substantial increase in the number of children eligible for admission into feeding programs, the quality of care might be compromised and resources diluted. WHO recommends that the new growth standards be used globally in all feeding programs for acutely malnourished children. The substantial increase in patient load expected with the adoption of the new standards underscores the need to monitor how rapidly international relief agencies and ministries of health are able to adapt in terms of enrollment rates, personnel resources, and financial expenditures. 
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